Gastric Cancer after Helicobacter pylori Eradication: Characteristics, Diagnosis, and Management
Digestion · 24.11.2025 · 1-15
DOI: 10.1159/000549737 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Digestion, online erschienen am 24.11.2025. Verfasst von Seokho Myeong und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background: Helicobacter pylori eradication is one of the most well-established strategies for the prevention of gastric cancer and is recommended in several countries, particularly in high-risk countries. However, gastric cancer can still develop even after successful eradication. As H. pylori eradication has become more prevalent, the characterization, surveillance, and management strategies for gastric cancers that arise following eradication have emerged as important clinical challenges. Summary: Gastric cancers that develop after H. pylori eradication typically arise in the context of preexisting atrophic gastritis or intestinal metaplasia, high-risk background mucosa rather than obligate precursor lesions, reflecting a field effect that predispose gastric stem cells to malignant transformation. Although H. pylori eradication reduces the overall risk of gastric cancer, residual risk depends on the extent and severity of atrophy or intestinal metaplasia. Molecular changes, including persistent CpG island hypermethylation and aberrant miRNA expression, particularly within intestinal metaplasia, may persist after eradication. These cancers are mainly the intestinal type and frequently present as small, depressed, gastritis-like appearance or lesions covered by epithelium with low-grade atypia, making endoscopic diagnosis challenging. Risk prediction can be improved through endoscopic assessment of precancerous lesions, advanced high-resolution imaging endoscopy techniques, and molecular biomarkers. Given the persistent risk, individualized, risk-based long-term surveillance strategies are recommended, particularly for patients with extensive atrophy or intestinal metaplasia. Key Messages: (1) Despite H. pylori eradication, the risk of gastric cancer persists in patients with atrophic mucosal changes and intestinal metaplasia. (2) Gastric cancers after H. pylori eradication exhibit distinct endoscopic and pathological features compared to those without prior eradication, making early diagnosis challenging. (3) Risk stratification based on endoscopic assessment, advanced imaging, and molecular biomarkers can refine surveillance strategies, emphasizing the importance of long-term, personalized follow-up after eradication.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, parkjerry@catholic.ac.kr.
- Department of Medical Life Sciences, The Catholic University of Korea, Seoul, Republic of Korea, parkjerry@catholic.ac.kr.
Zitieren
APA
Myeong, S., Kim, I., Kang, D., Cho, Y. K., & Park, J. M. (2025). Gastric Cancer after Helicobacter pylori Eradication: Characteristics, Diagnosis, and Management. Digestion, 1-15. https://doi.org/10.1159/000549737
Vancouver
Myeong S, Kim I, Kang D, Cho YK, Park JM. Gastric Cancer after Helicobacter pylori Eradication: Characteristics, Diagnosis, and Management. Digestion. 2025:1-15. doi:10.1159/000549737
BibTeX
@article{Myeong2025,
author = {Myeong, Seokho and Kim, Ilsoo and Kang, Donghoon and Cho, Yu Kyung and Park, Jae Myung},
title = {Gastric Cancer after Helicobacter pylori Eradication: Characteristics, Diagnosis, and Management},
journal = {Digestion},
year = {2025},
pages = {1--15},
doi = {10.1159/000549737}
}
EUVIMED